today's Pick
US frees up another experimental Ebola drug
Publish Date: Aug 08, 2014
newvision
  • mail
  • img

WASHINGTON - US regulators loosened restrictions on a new experimental drug for treating Ebola, which may allow it to be tried on infected patients in West Africa, the company said yesterday.

The Canada-based company, Tekmira, said the US Food and Drug Administration changed the classification of its drug TKM-Ebola from full clinical hold to partial hold.

"This action enables the potential use of TKM-Ebola in individuals infected with Ebola virus," said a company statement.

Tests on monkeys have shown the drug provided 100 percent protection from an otherwise lethal dose of Ebola, the company said.

West Africa is experiencing the largest outbreak of Ebola in history. The virus has killed 932 people of more than 1,700 infected, and the disease continues to spread.

"This current outbreak underscores the critical need for effective therapeutic agents to treat the Ebola virus," said Mark Murray, CEO and president of Tekmira Pharmaceuticals.

"We recognize the heightened urgency of this situation, and are carefully evaluating options for use of our investigational drug within accepted clinical and regulatory protocols."

TKM-Ebola is being developed under a $140 million contract with the US Department of Defense's Medical Countermeasure Systems BioDefense Therapeutics Joint Product Management Office.

The drug, described as an anti-Ebola virus RNAi therapeutic, is designed to be given in multiple doses, which is not always practical in a mass outbreak.

However, there are no drugs on the market to treat Ebola and no vaccines against it.

The rapidly growing outbreak in West Africa has sped up the process of getting experimental therapies to market, though experts say it may be months before production can be scaled up and the drugs delivered to those in need.

The two American missionaries who were evacuated from Liberia in recent days were given a different experimental serum known as ZMapp.

Both Kent Brantly and Nancy Writebol are improving, but health authorities say it is too early to tell if the drug had anything to do with that.

Related Stories

Ebola discoverer says would sit next to victim

Too early to send experimental Ebola drug to Africa - Obama

 

The statements, comments, or opinions expressed through the use of New Vision Online are those of their respective authors, who are solely responsible for them, and do not necessarily represent the views held by the staff and management of New Vision Online.

New Vision Online reserves the right to moderate, publish or delete a post without warning or consultation with the author.Find out why we moderate comments. For any questions please contact digital@newvision.co.ug

  • mail
  • img
blog comments powered by Disqus
Also In This Section
Museveni calls for political mobilization against Ebola
PRESIDENT Yoweri Museveni has expressed sadness at the loss of lives in West Africa due to the Ebola outbreak and said that the people of Uganda stand with their brothers and sisters...
Minister orders musician’s arrest over x-rated video
IRRITATED by the recently released X-rated music video of little known city singer Panadol Extra, Fr. Simon Lokodo, the Minister of Ethics and Integrity, ordered the arrest of the singer...
THE highly contagious Ebola virus, which has killed more than 4,500 people in west Africa since December and has fueled global alarm...
Ugandan rebels spread fear with DR Congo massacres
You sent soldiers to wipe us out, but here we are." That was the chilling message from Ugandan rebels during the latest massacre in the northeastern Democratic Republic of Congo, according to one survivor...
Mbabazi steps aside as NRM secretary general
National Resistance Secretary General, Amama Mbabazi, has taken leave of absence from office....
Makerere university students strike
Makerere university students have gone on strike protesting a hike in graduation fees....
Do Ugandan tycoons prepare their children to take over their business empires?
Yes
No
Can't Say
follow us
subscribe to our news letter